NCT06261957进行中（未招募）3 期
A Randomized, Double-blind, Parallel Group, Multi-center Study to Evaluate the Long-term Safety of Salbutamol Rescue Medication When Administered Via Metered Dose Inhalers Containing the Propellant HFA-152a or Reference HFA-134a
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 412
- 试验地点
- 1
- 主要终点
- Number of participants with Adverse Events (AEs)
研究概览
简要总结
The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged >=18 years with asthma
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant of ≥18 years of age at the time of signing the informed consent or written informed consent is obtained from each study participant's legal guardian.
- •Asthma for ≥ 6 months, defined as:
- •Documented history of asthma, as defined by Global Initiative for Asthma (GINA) (GINA, 2023]
- •Receiving one of the following asthma treatments, at a stable dose (applicable to daily Inhaled corticosteroid (ICS), ICS/Long-acting bronchodilator (LABA), and ICS/LABA/Long-acting muscarinic antagonist [LAMA]), for at least 12 weeks prior to the screening visit, with treatment that is anticipated to remain stable for the duration of the study:
- •Short-Acting Beta-2-Adrenoreceptor Agonists (SABA) used as needed for asthma symptoms
- •Daily maintenance low to medium dose Inhaled corticosteroid (ICS) (low to medium dose ICS defined as 100-500 μg/day fluticasone propionate or equivalent as defined in the 2023 GINA guidelines [GINA, 2023], plus Short-Acting Beta-2-Adrenoreceptor Agonists (SABA), which is anticipated to remain stable for the duration of the study.
- •Daily maintenance low to medium dose ICS/ Long-acting bronchodilator (LABA) (low to medium dose ICS defined as 100-500 μg/day fluticasone propionate or equivalent as defined in the GINA guidelines [GINA, 2023] plus SABA, which is anticipated to remain stable for the duration of the study.
- •Daily maintenance ICS/LABA/LAMA (low to medium dose ICS defined as 100-500 µg/day fluticasone propionate or equivalent as defined in the GINA guidelines [GINA, 2023] plus SABA, which is anticipated to remain stable for the duration of the study.
- •Participants who utilize combination budesonide/formoterol as reliever therapy, whether or not this is in addition to a SABA - are not eligible for screening.
- •Participants who utilize ICS/SABA combination therapy as reliever therapy, in addition to low to medium dose ICS or ICS/LABA as maintenance, are only eligible if they agree to discontinue their ICS/SABA inhaler for the duration of the study (screening through follow-up).
- •Severity of disease assessed by the investigator by baseline pre-bronchodilator Forced expiratory volume in 1 second (FEV1)
- •Asthma Control Status
- •Asthma Control Questionnaire (ACQ) 6 score <1.5 at screening
- •Asthma that has remained stable with no severe exacerbations in the last 6 months. Severe exacerbation defined as:
- •Deterioration of asthma-requiring the use of systemic corticosteroids (tablets, suspension or injection), for at least 3 days, OR
- •An inpatient hospitalization or Emergency Department (ED) visit because of asthma, requiring systemic corticosteroids.
- •Evidence of reversibility of disease: Airway reversibility is defined as ≥12 percent (%) and ≥200 milliliter (mL) increase in FEV1 within 20 to 60 minutes following up to 4 inhalations of albuterol/salbutamol aerosol.
- •Participants on as-needed SABA only, or daily maintenance ICS (plus as needed SABA):
- •With a documented history of reversibility (as defined above) within 2 years will meet this inclusion criterion. Pre- and post-bronchodilator measurements will still be collected at screening to characterize the degree of reversibility.
- •Who do not have a documented history of reversibility within the past 2 years will need to demonstrate reversibility during the screening period.
- •SABA should be withheld for ≥6 hours
- •Participants on daily maintenance ICS/LABA or ICS/LABA/LAMA:
- •Participants on daily maintenance ICS/LABA or ICS/LABA/LAMA:
- •Do not need to demonstrate reversibility in accordance with the above definition during the screening period. A reversibility maneuver will be performed to characterize the degree of post-bronchodilator change.
- •SABA should be withheld for ≥6 hours
- •LABA- and LAMA-containing medications should be withheld for >=24 hours for the characterization of post-bronchodilator change.
- •Participants should be able to withhold SABA for ≥6 hours and LABA-/ LAMA containing medications for ≥24 hours for the purposes of performing screening spirometry.
排除标准
- •A history of life-threatening asthma or asthma that is unstable in the opinion of the investigator.
- •Other significant pulmonary diseases to include (but not limited to): pneumothorax, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, tuberculosis or other respiratory abnormalities other than asthma.
- •Respiratory Infection: Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of screening that led to a change in asthma management, OR in the opinion of the Investigator, is expected to affect the participant's asthma status, OR the participant's ability to participate in the study.
- •Asthma Exacerbation: Any severe asthma exacerbation within 6 months prior to screening.
- •Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) Biologic/immunosuppressive therapies used for the treatment of respiratory diseases during the 6 months, or 5 half-lives-whichever is longer-prior to start of the study.
研究组 & 干预措施
Salbutamol Test Arm
Experimental
干预措施: Salbutamol HFA-152a (Drug)
Salbutamol Reference Arm
Active Comparator
干预措施: Salbutamol HFA-134a (Drug)
结局指标
主要结局
Number of participants with Adverse Events (AEs)
时间窗: Up to 3 months
次要结局
- Number of participants with Serious Adverse Events (SAEs)(Up to 3 months)
- Absolute Values of Minimum serum potassium (milliequivalents per litre [mEq/L])(Up to 3 months)
- Absolute values of serum potassium (milligrams per decilitre)(Up to 3 months)
- Change from baseline in serum potassium (milligrams per decilitre)(Baseline (Day 1) and up to 3 months)
- Absolute value of haematology parameter: Platelet count (cells per microliter)(Up to 3 months)
- Absolute value of haematology parameter: Red Blood Cell Count (RBC) (million cells per microliter)(Up to 3 months)
- Absolute value of haematology parameter: Mean Corpuscle Volume (MCV) (Femtoliters)(Up to 3 months)
- Absolute value of haematology parameter: Mean Corpuscle haemoglobin (MCH) (Picograms)(Up to 3 months)
- Absolute values of haematology parameter: Reticulocytes (Percentage of reticulocytes)(Up to 3 months)
- Absolute values of haematology parameters: Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (giga cells per litre)(Up to 3 months)
- Absolute values of haematology parameter: haemoglobin (Hgb) (grams per decilitre)(Up to 3 months)
- Absolute values of haematology parameter: haematocrit (Proportion of red blood cells in blood)(Up to 3 months)
- Absolute values of Clinical Chemistry parameters: Glucose (non-fasting), Blood Urea Nitrogen (BUN), Creatinine, Sodium, Potassium, Calcium, Direct Bilirubin and Total Bilirubin (milligrams per decilitre)(Up to 3 months)
- Absolute values of Aspartate aminotransferase/serum glutamic-oxaloacetic transaminase, Alanine aminotransferase/serum glutamic-pyruvic transaminase, Alkaline phosphatase, Creatine phosphokinase (International Units per litre)(Up to 3 months)
- Absolute value of routine urinalysis: potential of hydrogen (pH)(Up to 3 months)
- Number of participants with abnormal urinalysis dipstick results: glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase(Up to 3 months)
- Change from baseline in haematology parameter: Platelet count (cells per microliter)(Baseline (Day 1) and up to 3 months)
- Change from baseline in haematology parameter: Red Blood Cell Count (RBC) (million cells per microliter)(Baseline (Day 1) and up to 3 months)
- Change from baseline in haematology parameter: Mean Corpuscle Volume (MCV) (Femtoliters)(Baseline (Day 1) and up to 3 months)
- Change from baseline in haematology parameter: Mean Corpuscle haemoglobin (MCH) (Picograms)(Baseline (Day 1) and up to 3 months)
- Change from baseline in haematology parameter: Reticulocytes (Percentage of reticulocytes)(Baseline (Day 1) and up to 3 months)
- Change from baseline in haematology parameters: Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (giga cells per litre)(Baseline (Day 1) and up to 3 months)
- Change from baseline in haematology parameter: haemoglobin (Hgb) (grams per decilitre)(Baseline (Day 1) and up to 3 months)
- Change from baseline in haematology parameters: haematocrit (Proportion of red blood cells in blood)(Baseline (Day 1) and up to 3 months)
- Change from baseline in Clinical Chemistry parameters: Glucose (non-fasting), Blood Urea Nitrogen (BUN), Creatinine, Sodium, Potassium, Calcium, Direct Bilirubin and Total Bilirubin (milligrams per decilitre)(Baseline (Day 1) and up to 3 months)
- Change from baseline in Aspartate aminotransferase/ serum glutamic-oxaloacetic transaminase,Alanine aminotransferase/serum glutamic-pyruvic transaminase, Alkaline phosphatase, Creatine phosphokinase (International Units per litre)(Baseline (Day 1) and up to 3 months)
- Change from baseline in routine urinalysis: pH(Baseline (Day 1) and up to 3 months)
- Absolute values for vital signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) [millimeters of mercury (mm Hg)](Up to 3 months)
- Absolute values for vital sign: pulse rate [beats per min (bpm)](Up to 3 months)
- Change from baseline in vital signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) [millimeters of mercury (mm Hg)](Baseline (Day 1) and up to 3 months)
- Change from baseline in vital sign: pulse rate [beats per min (bpm)](Baseline (Day 1) and up to 3 months)
- Absolute values for 12 Lead Electrocardiograms (ECGs) in Corrected QT interval (QTc) (milliseconds)(Up to 3 months)
- Absolute values for heart rate [beats per min (bpm)](Up to 3 months)
- Change from baseline for 12 Lead ECGs in QTc (milliseconds)(Baseline (Day 1) and up to 3 months)
- Change from baseline for heart rate [beats per min (bpm)](Baseline (Day 1) and up to 3 months)
- Change from baseline in Asthma Control Questionnaire (ACQ-6) score(Baseline (Day 1) and up to 3 months)
- Change from baseline for pre-bronchodilator Forced expiratory volume in 1 second (FEV1)(Baseline (Day 1) and up to 3 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
28 Day Repeat Dose in Cystic Fibrosis PatientsCystic FibrosisNCT00903201GlaxoSmithKline146
已完成
1 期
Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese SubjectsOverweight and ObesityNAFLDHyperlipidemiaNCT04686994Gannex Pharma Co., Ltd.20
已完成
2 期
Efficacy Study in Allergic Rhinitis Patients After Intranasal Administration of AZD8848Allergic RhinitisNCT01185080AstraZeneca93
已完成
1 期
Safety and Tolerability of IBI355 in Healthy VolunteersHealthyNCT06416787Innovent Biologics (Suzhou) Co. Ltd.32
已完成
1 期
Safety and Tolerability of IBI355 in Patients With Primary Sjogren's SyndromePrimary Sjögren's SyndromeNCT06484855Innovent Biologics (Suzhou) Co. Ltd.30